Multivariable analyses in the primary cohort of 210 CN-AML patients
| Variable . | RFS, n = 133 . | OS, n = 210 . | EFS, n = 210 . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| LEF1 expression, high vs low | 0.50 (0.30-0.83) | .007 | 0.60 (0.40-0.90) | .01 | 0.58 (0.40-0.83) | .003 |
| Age, per 10-y increase | 1.28 (1.08-1.53) | .006 | 1.26 (1.09-1.46) | .002 | 1.31 (1.14-1.49) | < .001 |
| Sex, male vs female | 1.13 (0.69-1.86) | .62 | 1.08 (0.73-1.59) | .70 | 1.20 (0.84-1.71) | .31 |
| WBC, logarithmic, per 10-fold increase | 1.39 (0.91-2.13) | .13 | 1.33 (0.96-1.87) | .09 | 1.24 (0.92-1.70) | .15 |
| Secondary or therapy-related AML, vs de novo AML | nd* | 1.43 (0.68-3.02) | .34 | 0.94 (0.45-1.95) | .87 | |
| NPM1 mutated/FLT3-ITD negative, vs other genotypes | 0.27 (0.14-0.51) | < .001 | 0.43 (0.25-0.73) | .002 | 0.38 (0.24-0.62) | < .001 |
| CEBPA mutation | ||||||
| Monoallelic vs absent | 0.38 (0.14-1.05) | .06 | 0.52 (0.24-1.13) | .10 | 0.53 (0.26-1.07) | .08 |
| Biallelic vs absent | 0.52 (0.16-1.69) | .27 | 0.38 (0.14-1.00) | .05 | 0.79 (0.37-1.72) | .55 |
| IDH1 mutation, present vs absent | 1.91 (0.81-4.49) | .14 | 1.80 (0.90-3.61) | .10 | 1.87 (1.01-3.44) | .04 |
| IDH2 mutation, present vs absent | 0.98 (0.49-2.00) | .97 | 0.78 (0.43-1.41) | .41 | 0.90 (0.54-1.51) | .69 |
| MLL-PTD, present vs absent | 1.15 (0.51-2.62) | .73 | 1.20 (0.66-2.16) | .56 | 1.38 (0.80-2.37) | .24 |
| ERG expression, high vs low | 1.57 (0.86-2.86) | .14 | 1.42 (0.91-2.22) | .13 | 1.42 (0.94-2.14) | .10 |
| BAALC expression, high vs low | 0.93 (0.53-1.62) | .79 | 1.28 (0.80-2.03) | .29 | 1.07 (0.71-1.63) | .73 |
| MN1 expression, high vs low | 1.59 (0.92-2.77) | .10 | 0.95 (0.61-1.47) | .81 | 1.28 (0.86-1.92) | .23 |
| EVI1 overexpression, present vs absent | nd* | 1.15 (0.55-2.41) | .71 | 1.23 (0.63-2.40) | .54 | |
| Variable . | RFS, n = 133 . | OS, n = 210 . | EFS, n = 210 . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| LEF1 expression, high vs low | 0.50 (0.30-0.83) | .007 | 0.60 (0.40-0.90) | .01 | 0.58 (0.40-0.83) | .003 |
| Age, per 10-y increase | 1.28 (1.08-1.53) | .006 | 1.26 (1.09-1.46) | .002 | 1.31 (1.14-1.49) | < .001 |
| Sex, male vs female | 1.13 (0.69-1.86) | .62 | 1.08 (0.73-1.59) | .70 | 1.20 (0.84-1.71) | .31 |
| WBC, logarithmic, per 10-fold increase | 1.39 (0.91-2.13) | .13 | 1.33 (0.96-1.87) | .09 | 1.24 (0.92-1.70) | .15 |
| Secondary or therapy-related AML, vs de novo AML | nd* | 1.43 (0.68-3.02) | .34 | 0.94 (0.45-1.95) | .87 | |
| NPM1 mutated/FLT3-ITD negative, vs other genotypes | 0.27 (0.14-0.51) | < .001 | 0.43 (0.25-0.73) | .002 | 0.38 (0.24-0.62) | < .001 |
| CEBPA mutation | ||||||
| Monoallelic vs absent | 0.38 (0.14-1.05) | .06 | 0.52 (0.24-1.13) | .10 | 0.53 (0.26-1.07) | .08 |
| Biallelic vs absent | 0.52 (0.16-1.69) | .27 | 0.38 (0.14-1.00) | .05 | 0.79 (0.37-1.72) | .55 |
| IDH1 mutation, present vs absent | 1.91 (0.81-4.49) | .14 | 1.80 (0.90-3.61) | .10 | 1.87 (1.01-3.44) | .04 |
| IDH2 mutation, present vs absent | 0.98 (0.49-2.00) | .97 | 0.78 (0.43-1.41) | .41 | 0.90 (0.54-1.51) | .69 |
| MLL-PTD, present vs absent | 1.15 (0.51-2.62) | .73 | 1.20 (0.66-2.16) | .56 | 1.38 (0.80-2.37) | .24 |
| ERG expression, high vs low | 1.57 (0.86-2.86) | .14 | 1.42 (0.91-2.22) | .13 | 1.42 (0.94-2.14) | .10 |
| BAALC expression, high vs low | 0.93 (0.53-1.62) | .79 | 1.28 (0.80-2.03) | .29 | 1.07 (0.71-1.63) | .73 |
| MN1 expression, high vs low | 1.59 (0.92-2.77) | .10 | 0.95 (0.61-1.47) | .81 | 1.28 (0.86-1.92) | .23 |
| EVI1 overexpression, present vs absent | nd* | 1.15 (0.55-2.41) | .71 | 1.23 (0.63-2.40) | .54 | |
Multiple imputations using a predictive mean matching algorithm were used in the case of missing covariables.
CN-AML indicates cytogenetically normal acute myeloid leukemia; RFS, relapse-free survival; OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; WBC, white blood cell count; ITD, internal tandem duplication; nd, not done; and PTD, partial tandem duplication.
This variable could not be included in the model for RFS due to the small patient number.